BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3093% above fair value
$61.43+2.92 (+4.99%)
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
BioMarin Pharmaceutical pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
BioMarin Pharmaceutical's pe ratio was 153.5× on Nov 11, 2026, against 21.1× a year earlier. Over the last 5 years it ranged from 15.9× to 478.1×, with a median of 76.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 153.5× | +131.1 |
| 2025 | Dec 31, 2025 | 22.4× | −16.9 |
| 2024 | Dec 31, 2024 | 39.4× | −85.9 |
| 2023 | Dec 29, 2023 | 125.2× | −121.2 |
| 2022 | Dec 30, 2022 | 246.4× | +227.8 |
| 2021 | Oct 29, 2021 | 18.6× | −1.5 |
| 2020 | Dec 31, 2020 | 20.1× | −3.0 |
| 2011 | Oct 31, 2011 | 23.0× | +7.5 |
| 2010 | Dec 31, 2010 | 15.6× | −49.3 |
| 2009 | Dec 31, 2009 | 64.9× | – |
See a number that looks wrong?